A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

NCT06605703 · Completed

Last updated 2026-05-28

This clinical trial is testing different weight management strategies in adults with obesity or overweight after stopping semaglutide or tirzepatide.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 226 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2026-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06605703 ↗

Description as written by the study sponsor.

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

Treatments tested

WW Clinic Behavioral

Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
Bupropion-Naltrexone Drug

Bupropion-Naltrexone
Bupropion-Naltrexone-Metformin Drug

Bupropion-Naltrexone-Metformin

Main thing measured	Percent body weight change at 12 weeks
Sponsor	WW International Inc
Conditions studied	Obesity, Overweight
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06605703 ↗